Related Experiment Video
Updated: May 30, 2026
07:50
A Rapid Method for Multispectral Fluorescence Imaging of Frozen Tissue Sections
Published on: March 30, 2020
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents
Thapi D Rao1, Nestor Rosales, David R Spriggs
1Laboratory of Clinical Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Molecular Cancer Therapeutics
|August 6, 2011
Summary
This study developed a novel screening method to find cancer drugs targeting MUC16-expressing cells. The approach identified compounds selectively killing MUC16-positive ovarian cancer cells, offering new therapeutic strategies.
Area of Science:
- Oncology
- Drug Discovery
- Molecular Biology
Background:
- Current cancer chemotherapies lack specificity, targeting general cellular mechanisms rather than unique cancer cell features.
- Genomic advancements reveal new tumor targets, enabling the development of drugs with specific cancer cell targeting capabilities.
- MUC16/CA125 is identified as a marker and driver of transformation, presenting a target for selective drug development.
Purpose of the Study:
- To design and validate a target-based high-content screen to identify compounds differentially affecting MUC16-expressing cells.
- To discover novel drug candidates with selective cytotoxicity against MUC16-positive or MUC16-negative ovarian cancer cells.
- To evaluate an innovative isogenic, dual-color fluorescence strategy for identifying targeted cancer therapeutics.
Main Methods:
- A coculture assay using isogenic ovarian cancer cells (MUC16-positive and MUC16-negative) in a 384-well plate format.
- High-throughput screening of a small molecule library using Preferential Score analysis to identify differentially cytotoxic compounds.
- Confirmation of MUC16-selective compounds through caspase-induction assays and comparison of results in single and coculture settings.
Main Results:
- Identification of compounds preferentially cytotoxic to MUC16(+) or MUC16(-) ovarian cancer cells.
- Discovery of compounds effective against both MUC16-positive and MUC16-negative ovarian cancer cells.
- Validation of MUC16-targeting compounds using caspase-induction assays, confirming selective cytotoxicity.
Conclusions:
- The developed isogenic, dual-color fluorescence screening strategy is an effective method for identifying novel drug candidates.
- This approach enables the selective targeting of cancer cells based on unique molecular properties, such as MUC16 expression.
- The findings pave the way for developing more specific and effective cancer therapies, particularly for ovarian cancer.
